Virax Biolabs Group Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.5M
- Price
- $3.19
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.54%
- Volume
- 120.6K
About
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Quick stats
Shares outstanding796.9K
Computed float735.9K
Float / shares92.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001885827
Websitehttps://viraxbiolabs.com
AI Summary
AI-generated1/14
minorneutraloperations update
Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution
RedChip Companies will host an investor webinar for Virax Biolabs Group on August 25, featuring CEO James Foster to discuss the company's financial and strategic position.
Foster plans to address the company's recent regaining of compliance with Nasdaq's minimum bid price requirement and outline development plans for the ViraxImmune and ImmuneSelect programs.
The discussion will also cover the recently announced commercial supply framework with Fosun Diagnostics covering six Southeast Asian markets.
Red flags
- Paid investor relations promotion via RedChip